Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
Data release and conference call on Monday January 13, 2020
LONDON, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, will release results on Monday, January 13, 2020 at 5.00 am GMT from a Phase 2b dose-ranging study evaluating nebulized ensifentrine as an add-on to treatment with a long acting bronchodilator in patients with moderate-to-severe COPD. Also on January 13, 2020, Jan-Anders Karlsson, PhD, CEO of Verona Pharma, will host an investment community conference call to discuss the data.
Conference call and Webcast Information
Analysts and investors may participate in the conference call by using the conference ID and numbers below:
|Date:||Monday, January 13, 2020|
|Time:||2.00 pm GMT / 9.00 am ET / 6.00 am PST|
|Conference Call ID:||2874368|
- 866 940 4574 for callers in the United States
- 0800 028 8438 for callers in the United Kingdom
- 0800 181 5287 for callers in Germany
A live webcast will be available on the Events and Presentations page on the Investors section of the Company's website at www.veronapharma.com and an audio replay will be available there for 30 days. In addition, copies of the data slides and press release will be available on the Company’s website.
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Verona Pharma is currently in Phase 2 development with three formulations of ensifentrine for the treatment of COPD: nebulized, dry powder inhaler, and pressurized metered-dose inhaler. Ensifentrine also has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, the development of ensifentrine, the progress and timing of clinical trials and data, estimates of medical costs for COPD, the potential for ensifentrine to be a first-in-class phosphodiesterase 3 and 4 inhibitor, and to be the first therapy for the treatment of respiratory diseases to combine bronchodilator and anti-inflammatory activities in a single molecule, and the potential application of ensifentrine for the treatment of cystic fibrosis, asthma and other respiratory diseases.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of ensifentrine, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of ensifentrine, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with ensifentrine, which could adversely affect our ability to develop or commercialize ensifentrine; potential delays in enrolling patients, which could adversely affect our research and development efforts and the completion of our Phase 2b trial; we may not be successful in developing ensifentrine for multiple indications; our ability to obtain approval for and commercialize ensifentrine in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; material differences between our “top-line” data and final data; our reliance on third parties, including clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize ensifentrine; and lawsuits related to patents covering ensifentrine and the potential for our patents to be found invalid or unenforceable. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 19, 2019, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
For further information, please contact:
|Verona Pharma plc||Tel: +44 (0)20 3283 4200|
|Jan-Anders Karlsson, Chief Executive Officerfirstname.lastname@example.org|
|David Moskowitz, VP Capital Markets Strategy & Investor Relations (Investor enquiries)|
Victoria Stewart, Director of Communications (Media Enquiries)
|N+1 Singer |
(Nominated Adviser and UK Broker)
|Tel: +44 (0)20 3283 4200|
|Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance)|
|Mia Gardner (Corporate Broking)|
|Optimum Strategic Communications|
(European Media and Investor Enquiries)
|Tel: +44 (0)20 950 9144 |
|Mary Clark / Eva Haas / Hollie Vile|
(US Investor Enquiries)
|Tel: +1 212-600-1902|
|Stephanie Marks / Kimberly Minarovich / Michael Barron|